Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Galsky · SciRah

Researcher profile · Semantic Scholar

M. Galsky

Share profile

M. Galsky — researcher profile on SciRah

h-index: 74
Works: 962
Citations: 32K

Most-cited papers

Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.
C. Vulsteke, N. Adra, P. Danchaivijitr, M. Sabadash +22 more
2026New England Journal of Medicine96 citations
Semantic Scholar
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274.
M. Galsky, J. E. Gschwend, M. Milowsky, M. Schenker +17 more
2025Annals of Oncology56 citations Open access
Semantic Scholar
Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA.
T. Powles, M. S. van der Heijden, Ying Wang, James W. F. Catto +16 more
2025Journal of Clinical Oncology36 citations Open access
Semantic Scholar
Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study.
M. Galsky, B. Valderrama, M. Maruzzo, Albert Font-Pous +16 more
2026Journal of Clinical Oncology30 citations
Semantic Scholar
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study.
Shilpa Gupta, Y. Loriot, M. S. van der Heijden, J. Bedke +21 more
2025The Lancet Oncology30 citations Open access
Semantic Scholar
Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer.
S. Daneshmand, A. Kamat, N. Shore, Joshua J. Meeks +16 more
2025Urologic oncology25 citations Open access
Semantic Scholar
Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer.
M. Galsky, B. Valderrama, M. Maruzzo, Albert Font +23 more
2026New England Journal of Medicine15 citations
Semantic Scholar
Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer
M. Galsky, S. Izadmehr, Meng-Gang Yu, S. Curtis +24 more
2026Proceedings of the National Academy of Sciences of the United States of America15 citations Open access
Semantic Scholar
Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma
van der Heijden, T. Powles, S. Gupta, Y. Loriot +21 more
2025ESMO Open15 citations Open access
Semantic Scholar
Pathogenic Genomic Alterations in Circulating Tumor DNA Predict Overall Survival in Men with Metastatic Castrate-resistant Prostate Cancer
Susan Halabi, Si-Yuan Guo, Bin Luo, Chen-Xi Yu +14 more
2025European Urology14 citations Open access
Semantic Scholar
Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone from the CheckMate 901 Trial.
M. Galsky, M. S. van der Heijden, T. Powles, M. Claps +16 more
2025European Urology12 citations Open access
Semantic Scholar
Clinical utility of tumour‐informed circulating tumour DNA in patients with testicular cancer
Reuben Ben-David, A. Eraky, B. Hug, M. Galsky +5 more
2025BJU International11 citations
Semantic Scholar
Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA.
M. Galsky, M. S. van der Heijden, James W. F. Catto, H. Al-Ahmadie +16 more
2025Journal of Clinical Oncology9 citations
Semantic Scholar
Nivolumab plus ipilimumab (NIVO+IPI) vs gemcitabine-carboplatin (gem-carbo) chemotherapy for previously untreated unresectable or metastatic urothelial carcinoma (mUC): Final results for cisplatin-ineligible patients from the CheckMate 901 trial.
M. S. van der Heijden, M. Galsky, T. Powles, A. Necchi +16 more
2025Journal of Clinical Oncology7 citations
Semantic Scholar
Urinary tumor DNA (utDNA) and circulating tumor DNA (ctDNA) in patients (pts) with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA.
M. S. van der Heijden, M. Galsky, Ricky S. Joshi, J. W. Catto +14 more
2026Journal of Clinical Oncology6 citations Open access
Semantic Scholar
Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer
M. Galsky, Mark Kockx, J. Roels, R. VanElzen +23 more
2025Cancer immunology research6 citations Open access
Semantic Scholar
Adjuvant nivolumab (NIVO) vs placebo (PBO) for high-risk muscle-invasive urothelial carcinoma (MIUC): Additional efficacy outcomes including overall survival (OS) in patients (pts) with muscle-invasive bladder cancer (MIBC) from CheckMate 274.
M. Milowsky, M. Galsky, J. Witjes, J. E. Gschwend +15 more
2025Journal of Clinical Oncology5 citations
Semantic Scholar
EV-302: Long-term subgroup analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).
J. Bedke, T. Powles, B. Valderrama, Shilpa Gupta +16 more
2025Journal of Clinical Oncology5 citations Open access
Semantic Scholar
The role of HER2-targeted therapy in urothelial carcinomas
J. Aragon-Ching, M. Galsky
2025Expert Opinion on Emerging Drugs5 citations
Semantic Scholar
A Pilot Study of the Combination of 5-Azacitidine and All-trans Retinoic Acid in Biochemically Recurrent Prostate Cancer
V. Patel, Deepak K. Singh, Himanshu Joshi, Nyima Sherpa +8 more
2025medRxiv4 citations Open access
Semantic Scholar
Sexual Health Outcomes in Sexual Minority and Heterosexual Men After Prostate Radiation Therapy.
D. Dickstein, T. Kapouranis, Keith M Sigel, C. Wheldon +11 more
2025International Journal of Radiation Oncology, Biology, Physics4 citations
Semantic Scholar
Phase 1/2 Duravelo-1 study: Preliminary results of nectin-4–targeting zelenectide pevedotin (BT8009) plus pembrolizumab in previously untreated, cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer.
P. Giannatempo, M. Galsky, Ignacio Durán, V. Boni +9 more
2025Journal of Clinical Oncology4 citations Open access
Semantic Scholar
Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer
M. Galsky, S. Izadmehr, Meng-Gang Yu, S. Curtis +24 more
2026medRxiv3 citations Open access
Semantic Scholar
NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors.
Xin Gao, A. Patnaik, N. Lakhani, J. Call +16 more
2025Journal of Clinical Oncology3 citations
Semantic Scholar
The Evolving Treatment Paradigm for Upper Tract Urothelial Carcinoma.
Saad O. Atiq, M. Galsky
2025European Urology Focus3 citations
Semantic Scholar
Prostate cancer in situ autovaccination with the intratumoral viral mimic poly-ICLC: Modulating the cold tumor microenvironment.
S. Nair, Dimple Chakravarty, Sreekumar Balan, Alexander Hakansson +40 more
2025i Medicina3 citations Open access
Semantic Scholar
Circulating tumor DNA–based clinical-genetic (CG) prognostic model for radiographic progression-free survival (rPFS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Analysis of Alliance A031201.
S. Halabi, Mengqi Xie, Chen-Xi Yu, Si-Yuan Guo +16 more
2026Journal of Clinical Oncology2 citations
Semantic Scholar
RC48G001: A phase 2 study of disitamab vedotin in HER2-expressing previously treated advanced UC.
T. Powles, V. Koshkin, J. Rosenberg, Nobuaki Matsubara +16 more
2026Journal of Clinical Oncology2 citations Open access
Semantic Scholar
Initial results from NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4, in participants with advanced or metastatic urothelial carcinoma.
G. Iyer, Xin Gao, Alexander Z. Wei, Inkeun Park +16 more
2026Journal of Clinical Oncology2 citations
Semantic Scholar
A phase 2 trial of androgen deprivation therapy interruption in patients responding exceptionally to androgen receptor pathway inhibitor in metastatic hormone-sensitive prostate cancer (A-DREAM / Alliance A032101).
A. Choudhury, K. Ballman, Melissa A. Reimers, A. Laccetti +16 more
2026Journal of Clinical Oncology2 citations
Semantic Scholar
IZABRIGHT-Bladder01: A randomized, open-label, phase 2/3 trial of izalontamab brengitecan (iza-bren; BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), vs platinum-based chemotherapy (PBC) for patients (pts) with advanced urothelial cancer (aUC) and disease progression on or after i
T. Powles, J. Rosenberg, Shilpa Gupta, Y. Loriot +10 more
2026Journal of Clinical Oncology2 citations
Semantic Scholar
Neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab for participants with muscle-invasive bladder cancer who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study.
Christopher J. Hoimes, M. Galsky, B. Valderrama, M. Maruzzo +16 more
2026Journal of Clinical Oncology2 citations
Semantic Scholar
SASANLIMAB IN COMBINATION WITH BACILLUS CALMETTE-GUÉRIN IMPROVES EVENT-FREE SURVIVAL VERSUS BACILLUS CALMETTE-GUÉRIN AS STANDARD OF CARE IN HIGH-RISK NON- MUSCLE-INVASIVE BLADDER CANCER: PHASE 3 CREST STUDY RESULTS
N. Shore, T. Powles, J. Bedke, M. Galsky +17 more
2025Journal of Urology2 citations
Semantic Scholar
Survey-based study of treatment sequencing after first-line (1L) enfortumab vedotin/pembrolizumab (EVP) in the evolving landscape of locally advanced/metastatic (la/m) urothelial cancer (UC).
P. Chablani, A. Khaki, Karine Tawagi, P. Grivas +7 more
2025Journal of Clinical Oncology2 citations
Semantic Scholar
3068O Adjuvant nivolumab vs placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274
M. Galsky, J. Gschwend, M. Milowsky, M. Schenker +16 more
2025Annals of Oncology2 citations Open access
Semantic Scholar
Sasanlimab in combination with bacillus Calmette-Guérin (BCG) in BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC): Event-free survival (EFS) subgroup analyses based on disease stage from the CREST study.
T. Powles, N. Shore, J. Bedke, M. Galsky +13 more
2025Journal of Clinical Oncology2 citations
Semantic Scholar
Quantitative pre-cystectomy ctDNA levels for identification of ctDNA-positive patients with surgically curable loco-regional disease versus those with occult micrometastatic progression.
Ruveyda Ayasun, Eric J. Miller, Lexi Weintraub, Lydia Wu +10 more
2026Journal of Clinical Oncology1 citations
Semantic Scholar
Phase 2 trial of pembrolizumab (P) with response-guided bladder-sparing in patients with muscle-invasive bladder cancer (MIBC; HCRN GU 20-444).
Jonathan F. Anker, Jennifer King, A. Tripathi, S. Izadmehr +16 more
2026Journal of Clinical Oncology1 citations
Semantic Scholar
Pathological outcomes and disease-free survival (DFS) in KEYNOTE-905: Neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible.
A. Ullén, C. Vulsteke, J. Bedke, Steffen Rausch +15 more
2026Journal of Clinical Oncology1 citations
Semantic Scholar
ASPIRE: A randomized phase III trial of androgen deprivation therapy (ADT) plus apalutamide (A) with or without docetaxel (D) in metastatic castration-sensitive prostate cancer (mCSPC) stratified by tumor suppressor gene alterations (Alliance A032302).
Deepak Kilari, K. Ballman, E. P. Gelmann, K. K. Zarrabi +16 more
2026Journal of Clinical Oncology1 citations
Semantic Scholar
A phase 2 randomized trial of radium-223 dichloride and cabozantinib in patients (pts) with renal cell carcinoma (RCC) with bone metastases (BM): RADICAL (Alliance A031801).
R. Mckay, Pamela J. Atherton, K. Ballman, H. Jacene +16 more
2026Journal of Clinical Oncology1 citations
Semantic Scholar
Perioperative Durvalumab in Bladder Cancer. Reply.
T. Powles, M. Galsky, M. S. van der Heijden
2025New England Journal of Medicine1 citations
Semantic Scholar
Association Between Circulating Tumor DNA and Clinical Outcomes with Adjuvant Immune Checkpoint Blockade in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by Cystectomy.
Jonathan F Anker, Meng-Gang Yu, M. Galsky
2025European Urology1 citations
Semantic Scholar
1318 Phase 1 clinical data show FX-909, a first-in-class oral PPARG inhibitor, drives immune modulation and pro-inflammatory cytokine induction in IO-experienced patients with advanced urothelial carcinoma
M. Milowsky, C. Mantia, E. Gjini, M. Galsky +10 more
2025Late-Breaking Abstracts1 citations Open access
Semantic Scholar
An evaluation of nivolumab plus gemcitabine and cisplatin in the treatment of advanced urothelial carcinoma
Eric J. Miller, M. Galsky
2025Expert Review of Anticancer Therapy1 citations
Semantic Scholar
3070MO Phase I study of LY3866288, a potent, highly isoform-selective FGFR3 inhibitor in FGFR3-altered advanced solid tumors (FORAGER-1): Dose optimization
A. Drakaki, S. H. Park, D. C. Gauna, A. Siefker-Radtke +16 more
2025Annals of Oncology1 citations Open access
Semantic Scholar
Phase II study of oral APL-1202 plus tislelizumab or tislelizumab alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC).
M. Galsky, J. Sfakianos, D. Ye, Badrinath R. Konety +6 more
2025Journal of Clinical Oncology1 citations Open access
Semantic Scholar
Assessing patient withdrawal in cancer clinical trials: A systematic evaluation of reasons and transparency in reporting.
A. Argulian, Alexander B. Karol, R. Paredes, Kasopefoluwa Y. Oguntuyo +6 more
2025Journal of Clinical Oncology1 citations
Semantic Scholar
MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy (PBC) in patients (pts) with locally advanced/metastatic urothelial cancer (la/mUC; Alliance A032001).
Shilpa Gupta, K. Ballman, A. Apolo, S. Sridhar +11 more
2026Journal of Clinical Oncology0 citations
Semantic Scholar
Zelenectide pevedotin (BT8009) monotherapy in previously treated metastatic urothelial carcinoma (mUC): Update on Duravelo-1.
Òscar Reig Torras, L. Crouzet, A. Necchi, C. Baldini +14 more
2026Journal of Clinical Oncology0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

T. Powles×17
Invite
T. Powles — researcher profile on SciRah
J. Bedke×12
Invite
J. Bedke — researcher profile on SciRah
B. Valderrama×9
Invite
B. Valderrama — researcher profile on SciRah
M. S. van der Heijden×9
Invite
M. S. van der Heijden — researcher profile on SciRah

×9

Invite

J. Rosenberg — researcher profile on SciRah

Invite

Y. Loriot — researcher profile on SciRah

J. Sfakianos×6

Invite

J. Sfakianos — researcher profile on SciRah

Invite

G. Iyer — researcher profile on SciRah

Invite

V. Atduev — researcher profile on SciRah

Blanca Homet Moreno×5

Invite

Blanca Homet Moreno — researcher profile on SciRah

Invite

Y. Zakharia — researcher profile on SciRah

Invite

A. Necchi — researcher profile on SciRah